Harry Lam

Harry Lam has extensive work experience in the biopharmaceutical industry. Harry currently holds the position of CTO and EVP Technical Operations at Acepodia, a role they have held since May 2022. Prior to this, they served as the CEO and Principal Consultant at LAM Pharma Consulting, Inc. starting in March 2017. From September 2018 to May 2022, they worked as the CTO and EVP Technical Operations at JW Therapeutics.

Harry's previous roles include Director and Head of Therapeutics Technical Operations at 23andMe from April 2017 to September 2018, CTO and VP CMC Development at Affinita Biotech from June 2016 to March 2017, and VP and Head of Manufacturing, Biologics at Sanofi from August 2015 to June 2016.

Harry also worked as the Vice President of Manufacturing Development & Technical Operations at Progenitor Cell Therapy from October 2014 to August 2015, Senior Vice President of Technical Operations at KaloBios from January 2014 to October 2014, and Vice President and Head of Manufacturing at Shire Regenerative Medicine from March 2013 to January 2014.

Harry's earlier experience includes roles at Genentech, A Member of the Roche Group, where they served as the Head of Commercial Drug Substance CMO from May 2012 to March 2013 and as the Senior Director of Global Biologics Drug Substance Manufacturing Science and Technology from April 2010 to May 2012.

Harry Lam has a PhD in Chemical Engineering from Rensselaer Polytechnic Institute. Harry also holds a BSc in Chemical Engineering from the University of Birmingham. However, specific start and end dates for both degrees are not provided.